Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,937 | -2,810 | -1,682 | -35,140 | -27,297 |
| Depreciation Amortization | 3 | 3 | 2 | 3,654 | 3,413 |
| Accounts receivable | 1 | -3 | N/A | 3 | 4 |
| Accounts payable and accrued liabilities | -159 | -251 | -19 | -773 | -92 |
| Other Working Capital | -799 | -1,065 | -409 | -6,254 | -2,201 |
| Other Operating Activity | 512 | 528 | 191 | 8,368 | 3,416 |
| Operating Cash Flow | $-4,379 | $-3,598 | $-1,917 | $-30,142 | $-22,757 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | 1,346 | -157 |
| Investing Cash Flow | $0 | $0 | $0 | $1,346 | $-157 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -18,105 | -18,105 |
| Common Stock Issued | N/A | N/A | N/A | 92 | 92 |
| Other Financing Activity | 0 | 0 | 0 | -125 | -125 |
| Financing Cash Flow | $0 | $N/A | $0 | $-18,138 | $-18,138 |
| Beginning Cash Position | 6,062 | 6,062 | 6,062 | 52,996 | 52,996 |
| End Cash Position | 1,683 | 2,464 | 4,145 | 6,062 | 11,944 |
| Net Cash Flow | $-4,379 | $-3,598 | $-1,917 | $-46,934 | $-41,052 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,379 | -3,598 | -1,917 | -30,142 | -22,757 |
| Capital Expenditure | N/A | N/A | N/A | -197 | -197 |
| Free Cash Flow | -4,379 | -3,598 | -1,917 | -30,339 | -22,954 |